Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.
The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:
- KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
- KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
- KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
- KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.
Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.
Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.
For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics (NASDAQ: KYMR) has outlined its key objectives for 2025, focusing on advancing its oral immunology programs. The company's lead candidate, KT-621, a STAT6 degrader, is in Phase 1 trials with data expected in Q2 2025, followed by Phase 1b trials in atopic dermatitis. Their KT-295 TYK2 degrader will advance to Phase 1 testing in Q2 2025, while KT-474/SAR444656 Phase 2b studies in hidradenitis suppurativa and atopic dermatitis are ongoing.
The company plans to disclose a novel oral immunology program in H1 2025. With an estimated $850 million in cash, Kymera has runway into mid-2027. Their strategy focuses on developing oral drugs with biologics-like activity for treating inflammatory diseases, particularly targeting conditions like atopic dermatitis, asthma, and other Th2-driven diseases affecting over 130 million patients globally.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET in San Francisco, California.
The company's Founder, President and CEO, Nello Mainolfi, PhD, will present an overview of Kymera's progress and outline anticipated milestones for 2025. Interested parties can access a live webcast of the presentation and Q&A session through the 'News and Events' section of Kymera's investor relations website. The presentation recording will be archived and available for later viewing.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has announced its participation in two major investor conferences this December. The company will engage in fireside chats at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 1:00 p.m. ET, and the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 4:15 p.m. ET. Live webcasts will be available on Kymera's website under the Investors section, with replays accessible after the events.
Kymera Therapeutics (NASDAQ: KYMR) has announced its participation in several major healthcare investor conferences this November. The company will engage in fireside chats at the Guggenheim Inaugural Healthcare Innovation Conference in Boston, Stifel 2024 Healthcare Conference in New York, Wolfe Research Healthcare Conference in New York, and Jefferies London Healthcare Conference in London. Additionally, they will attend the J.P. Morgan Equity Opportunities Forum in Miami for one-on-one meetings. Live webcasts of the presentations will be available on the company's website under the Investors section, with replays accessible after the events.
Kymera Therapeutics (NASDAQ: KYMR) reported Q3 2024 financial results and business updates. Key developments include FDA clearance and Phase 1 trial initiation for KT-621 (STAT6), with data expected in H1 2025. Sanofi is expanding KT-474 Phase 2 trials in HS and AD to Phase 2b studies. The company nominated KT-295 as its TYK2 degrader development candidate for Phase 1 trials in H1 2025.
The company will shift focus from oncology to immunology, seeking partners for oncology programs beyond Phase 1. Financial results show $3.7M in collaboration revenues, $62.5M net loss, and $911M in cash, providing runway into mid-2027.
Kymera Therapeutics (NASDAQ: KYMR) has initiated dosing in a Phase 1 clinical trial for KT-621, the first-ever oral STAT6 degrader to enter clinical development. The trial evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers through single and multiple ascending dose cohorts. KT-621 demonstrated dupilumab-like activity in preclinical models for treating TH2 immuno-inflammatory diseases, with potential as a convenient once-daily oral alternative to injectable treatments. Phase 1 data is expected in the first half of 2025.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), has scheduled its third quarter 2024 financial results announcement for October 31, 2024. The company will host a conference call at 8:30 a.m. ET on the same day. Investors can join via phone at +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International). A live webcast will be available on the company's website under the Investors section, with a replay available after the event.
Kymera Therapeutics announced three poster presentations at the EORTC-NCI-AACR Symposium, showcasing new preclinical data from its targeted protein degradation (TPD) platform. The presentations focus on KT-253, the company's MDM2 degrader currently in Phase 1 clinical trials for solid tumors and hematological malignancies. Using machine learning, researchers identified tumor types sensitive to KT-253, including acute myeloid leukemia, neuroendocrine tumors, and specific solid tumors. Additional presentations highlight the company's platform capabilities in developing CDK2 degraders and the effectiveness of MDM2 degraders in Merkel cell carcinoma.
Kymera Therapeutics (NASDAQ: KYMR) has announced FDA clearance of its Investigational New Drug (IND) application for KT-621, a first-in-class, oral STAT6 degrader. The company plans to initiate a Phase 1 clinical trial in healthy volunteers in October 2024, with data expected in the first half of 2025.
KT-621 has shown dupilumab-like activity and was well-tolerated in preclinical models of TH2 diseases. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of KT-621 compared to placebo.
Kymera believes that KT-621 has the potential to combine the complete pathway blockade of upstream biologics with the convenience of oral administration, potentially transforming the treatment paradigm for atopic and allergic diseases.
Kymera Therapeutics (NASDAQ: KYMR) presented preclinical data for KT-621, a potent, selective, oral STAT6 degrader, at the EADV Congress. KT-621 shows potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseases. The drug demonstrated strong degradation of STAT6 in human sensory neurons, inhibiting IL-13-induced itch- and pain-related gene transcripts, suggesting potential relief for atopic dermatitis symptoms.
Key highlights include:
- KT-621 expected to start Phase 1 in the second half of 2024, with data in the first half of 2025
- Preclinical studies show picomolar potency comparable or superior to dupilumab
- Demonstrated efficacy in atopic dermatitis and asthma mouse models
- Potential to expand patient access with a once daily, oral medicine for atopic dermatitis, asthma, and COPD
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics' main focus?
What is the Pegasus platform?
What are some key drugs in Kymera's pipeline?
What diseases is Kymera targeting?
What recent achievements has Kymera made?
How does Kymera's technology differ from conventional therapies?
Who are Kymera's partners?
Where is Kymera Therapeutics headquartered?
How is Kymera funded?
Where can I find more information about Kymera?
